Patents by Inventor Joerg REIMANN

Joerg REIMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD AND APPARATUS FOR GSM SILENT CALL PROLONGATION
    Publication number: 20240098808
    Abstract: A method for GSM silent call prolongation comprises a first step of activating a mobile station by establishing a mobile terminated call, MTC, communication link to the mobile station. The establishing of the MTC communication link is performed without sending an assignment command message to the mobile station. The method comprises a second step of sending a first unrealizable SETUP message to establish the silent call. The method comprises a third step of sending at least one more unrealizable SETUP message to prolong the silent call.
    Type: Application
    Filed: July 28, 2023
    Publication date: March 21, 2024
    Applicant: Rohde & Schwarz GmbH & Co. KG
    Inventor: Joerg REIMANN
  • HEAD-UP DISPLAY
    Publication number: 20230115930
    Abstract: A head-up display comprising an image generator with a light source, a tilted display, a display glass wherein the display glass has a wedged shape, a light trap, an optical system, and a transmissive screen is disclosed.
    Type: Application
    Filed: October 7, 2022
    Publication date: April 13, 2023
    Applicant: Continental Automotive Technologies GmbH
    Inventors: Willi Scheffler-Juschtschenko, Andreas Buechel, Christian Junge, Jörg Reimann, Eugen Vetsch
  • Delivery of immunogenic molecules vis HBsAg particles
    Patent number: 7029680
    Abstract: Compositions of HBsAg particles having biologically active molecules contained in the particles, and methods of their use, e.g. in stimulating enhanced immune responses, are described. Antigenic peptides contained in HBsAg particles were found to produce a CTL response where none was elicited by the peptide alone. Encapsulation of immunostimulating molecules, such as cytokines, greatly enhanced the CTL response evoked by the HBsAg particles themselves.
    Type: Grant
    Filed: February 2, 1999
    Date of Patent: April 18, 2006
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Jörg Reimann, Yechezkel Barenholz, Dvorah Diminsky, Reinhold Schirmbeck